From Treatment to Translation: Tailored PDX models from Patients Pretreated with Approved & Investigational Cancer Therapies
- Showcasing a novel drug delivery–driven tumor model approach, using a long lasting (28 day) bio-scaffold that adsorbs therapeutics, enables controlled release into the TME, recruits and activates immune cells, and reprograms tumor cells toward immune stimulatory states
- Demonstrating AI powered design of multimodal drug combinations, integrating human datasets and transcriptomic signatures to predict optimal scaffold loaded permutations that reshape the TME and enhance anti-tumor immunity
- Spotlighting the rationale for in vivo model selection, testing scaffold-based therapies in immunocompetent syngeneic models to better capture immune activation, TME remodelling and translational relevance